|
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
|
27 March 2023 |
|
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
|
17 March 2023 |
|
Novartis invests in early technical development capabilities for next-generation biotherapeutics
|
12 September 2022 |
|
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
|
25 August 2022 |
|
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
|
28 June 2022 |
|
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
|
20 June 2022 |
|
Sandoz announces new global 'Act4Biosimilars' initiative
|
03 June 2022 |
|
Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
|
22 April 2022 |
|
Novartis announces new organizational structure
|
05 April 2022 |
|
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
|
10 March 2022 |